Columbia Laboratories, Inc. (CBRX) Comments On FDA Decision On Adeza Biomedical (ADZA)'s Gestiva  
10/23/2006 10:32:01 AM

LIVINGSTON, N.J.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (“FDA”) has issued an approvable letter to Adeza Biomedical for their synthetic progestogen, 17-alpha-hydroxyprogesterone caproate (trademarked “Gestiva”), Adeza’s candidate for prevention of recurrent preterm birth. Final FDA action is subject to the completion of an additional animal study and certain other conditions.